A23V2400/515

BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS I797, METHOD FOR SEPARATION AND PURIFICATION THEREOF, AND USE THEREOF

Provided are a Bifidobacterium animalis subsp. lactis i797, a method for the separation and purification thereof, and a use thereof. The strain was is deposited in the China General Microbiological Culture Collection Center on Aug. 20, 2019, wherein the deposit address is Building 3, No. 1 Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC NO. 18403. The Bifidobacterium animalis subsp. lactis i797 can adjust the balance of intestinal flora, improve stool characteristics, and has a better survival rate in simulated digestive juice; in addition, after being stored at 37° C., a relatively high temperature which is suitable for the growth of lactic acid bacteria, same can successfully control post-acidification.

BIFIDOBACTERIA FOR TREATING CARDIAC CONDITIONS

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction and congestive heart failure.

SPERMIDINE-SUPPLEMENTED FOOD PRODUCTS
20230148258 · 2023-05-11 · ·

The nutritional food product compositions disclosed herein are provided to increase the levels of bioavailable spermidine. The compositions may include naturally-sourced spermidine in the form of a spermidine-containing fruit, vegetable, legume, and/or grain, one or more components that indirectly provides increased spermidine content, and a supplemental amount of spermidine. The compositions result in an improved profile panel of traditional biomarkers of general health and cellular health, higher levels of energy and alertness, reduced inflammation, and a stronger immune system.

METHODS FOR IMPROVING GASTROINTESTINAL BARRIER FUNCTION AND INHIBITING GROWTH OF ENTERIC PATHOGENIC BACTERIA
20230201280 · 2023-06-29 ·

Disclosed herein are methods for improving gastrointestinal barrier function, alleviating a gastrointestinal barrier dysfunction-associated disorder, and inhibiting growth of enteric pathogenic bacteria using a composition containing Lactobacillus rhamnosus MP108, Bifidobacterium longum subsp. infantis BLI-02, and Bifidobacterium animalis subsp. lactis BB-115, which are deposited at the China General Microbiological Culture Collection Center (CGMCC) respectively under accession numbers CGMCC 21225, CGMCC 15212, and CGMCC 21840. A number ratio of Lactobacillus rhamnosus MP108, Bifidobacterium longum subsp. infantis BLI-02, and Bifidobacterium animalis subsp. lactis BB-115 ranges from 1:0.2:0.67 to 1:9:9.

Composition for the treatment of atopic dermatitis comprising <i>Bifidobacterium animalis </i>subsp. <i>lactis </i>LM1017

A composition for the treatment of atopic dermatitis, the composition including, as an active ingredient, Bifidobacterium animalis subsp. lactis LM1017, and more specifically provided is a composition for the treatment of atopic dermatitis. The composition includes, as an active ingredient, a navel Bifidobacterium animalis subsp. lactis LM1017 which adjusts the NF-κB signal transduction pathway, and thus inhibits the expression of proinflammatory cytokines.

MATERNAL MILK POWDER CONTAINING PROBIOTICS AND PREBIOTICS AND PREPARATION METHOD THEREOF

A maternal milk powder and a preparation method thereof. Every 100 g of the maternal milk powder comprises: (0.1-10)×10.sup.8 CFU of probiotics, 1-10 g of FOS; wherein, probiotics comprise Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium animalis, and Bifidobacterium bifidum with a CFU ratio of 20-40:20-40:1-10:10-20:10-20:1-10. The maternal milk powder can effectively inhibit the proliferation of harmful bacteria in the intestinal tract of pregnant women, promote the health of intestinal microecology, improve immunity, relieve postpartum depression, etc. by adding six kinds of safe, stable and efficient probiotics and FOS.

COMPOSITION FOR PROMOTING DEFECATION AND USES THEREOF

A composition for promoting defecation includes a cell culture of at least one lactic acid bacterial strain which is substantially free of cells. The least one lactic acid bacterial strain is selected from the group consisting of Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9, and Lactobacillus acidophilus TYCA06, which are respectively deposited at the Bioresource Collection and Research Center (BCRC) under accession numbers BCRC 910437, BCRC 910645 and BCRC 910813. Also disclosed is a method for promoting defecation, including administering to a subject in need thereof an effective amount of the composition.

COMPOSITION AND METHOD FOR SYNBIOTICS SUPPLEMENT CONTAINING PROBIOTICS, DIGESTIVE ENZYMES, PREBIOTICS, YEAST, PROTEIN, B VITAMINS, AND FLAVORING AGENT
20220192246 · 2022-06-23 ·

A composition and method for use of a dietary supplement for promoting gastrointestinal health including effective amounts of probiotics, digestive enzymes, prebiotics, a dried, non-viable yeast, protein, B vitamins, and flavoring agent. The multi-strain of probiotics may be viable and dried bacteria like Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium animalis subsp. Lactis and Streptococcus thermophilus. The multistrain and multispecies probiotics may show synergistic effects. Digestive enzymes can be protease, lactase, cellulose, and/or pancreatin. The prebiotics may be inulin and other dietary fiber. The yeast may be Brewer's or Baker's yeast. The protein may be whey or soy or rice protein concentrates. The B vitamins may be Pantothenic Acid, Thiamine, Riboflavin, Niacinamide, Pyridoxine, Cyanocobalamin, Folic Acid and Biotin. The flavoring agent may be natural vanilla.

PROBIOTIC FOR INHIBITING GROWTH OF PROTEUS MIRABILIS, AND FERMENTATION BROTH AND APPLICATION THEREOF
20220192247 · 2022-06-23 ·

A probiotic for inhibiting growth of Proteus mirabilis, including a microorganism selected from the group consisting of Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus reuteri, Bifidobacterium animalis subsp. lactis, Bifidobacterium infantis, Bifidobacterium bifidum and a combination thereof. A fermentation broth and an application of the probiotic are further provided.

BIFIDOBACTERIA FOR TREATING DIABETES AND RELATED CONDITIONS
20230248786 · 2023-08-10 ·

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.